US2017204383A1PendingUtilityA1
C-RAF Mutants that Confer Resistance to RAF Inhibitors
Est. expiryMar 28, 2032(~5.6 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 35/00A61K 31/506C12N 9/12C12Q 1/6886C12Q 2600/106C12Y 207/11001C12Q 2600/156A61K 31/4184A61K 31/437G01N 33/5758G01N 33/5751
55
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Nucleic acids and proteins having a mutant C-RAF sequence, and methods of identifying patients having cancer who are likely to benefit from a combination therapy and methods of treatment are provided.
Claims
exact text as granted — not AI-modified1 . An expression vector comprising an isolated nucleic acid molecule encoding a mutant C-RAF polypeptide having C-RAF activity, wherein said mutant C-RAF polypeptide comprises at least one amino acid substitution as compared to a wild type C-RAF polypeptide comprising SEQ. ID. NO. 2, the at least one amino acid substitution conferring resistance to one or more RAF inhibitors on a cell expressing the mutant C-RAF polypeptide.
Join the waitlist — get patent alerts
Track US2017204383A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.